• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DECA

    Denali Capital Acquisition Corp.

    Subscribe to $DECA
    $DECA
    Blank Checks
    Finance

    IPO Year: 2022

    Exchange: NASDAQ

    Recent Analyst Ratings for Denali Capital Acquisition Corp.

    DatePrice TargetRatingAnalyst
    See more ratings

    Denali Capital Acquisition Corp. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      12/6/24 4:17:05 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 5:49:50 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 2:35:09 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 1:35:29 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      10/7/24 4:50:17 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      9/16/24 10:36:19 AM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form SC 13D filed by Denali Capital Acquisition Corp.

      SC 13D - Denali Capital Acquisition Corp. (0001913577) (Subject)

      9/9/24 4:11:56 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form SC 13G filed by Denali Capital Acquisition Corp.

      SC 13G - Denali Capital Acquisition Corp. (0001913577) (Subject)

      8/9/24 2:51:34 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Denali Capital Acquisition Corp. (Amendment)

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      2/22/24 8:48:24 AM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form SC 13G filed by Denali Capital Acquisition Corp.

      SC 13G - Denali Capital Acquisition Corp. (0001913577) (Subject)

      2/14/24 11:28:07 AM ET
      $DECA
      Blank Checks
      Finance

    Denali Capital Acquisition Corp. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:05:57 AM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 4 filed by Large owner Xu Jiandong

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:01:42 AM ET
      $DECA
      Blank Checks
      Finance

    Denali Capital Acquisition Corp. Financials

    Live finance-specific insights

    See more

    Denali Capital Acquisition Corp. SEC Filings

    See more
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

      As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

      11/6/24 12:24:36 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

      Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

      10/28/24 6:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

      Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

      10/16/24 4:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

      Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam

      9/3/24 9:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination

      Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion.  The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex

      9/3/24 9:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

      Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th

      7/2/24 5:15:30 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/22/25 5:10:19 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

      S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/21/25 5:17:32 PM ET
      $DECA
      Blank Checks
      Finance
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/15/25 9:20:12 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 425 filed by Denali Capital Acquisition Corp.

      425 - Denali Capital Acquisition Corp. (0001913577) (Subject)

      4/8/25 8:31:09 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 8-K filed by Denali Capital Acquisition Corp.

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/8/25 8:30:09 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form DEF 14A filed by Denali Capital Acquisition Corp.

      DEF 14A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      3/27/25 5:13:58 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form PRER14A filed by Denali Capital Acquisition Corp.

      PRER14A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      3/25/25 5:31:19 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form PRE 14A filed by Denali Capital Acquisition Corp.

      PRE 14A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      3/20/25 5:28:47 PM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 425 filed by Denali Capital Acquisition Corp.

      425 - Denali Capital Acquisition Corp. (0001913577) (Subject)

      2/11/25 4:15:55 PM ET
      $DECA
      Blank Checks
      Finance
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      2/11/25 4:12:36 PM ET
      $DECA
      Blank Checks
      Finance

    Denali Capital Acquisition Corp. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

      4/14/25 4:35:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.

      NEW YORK, NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that the Company's Extraordinary General Meeting of Shareholders (the "Extraordinary General Meeting") was convened on April 10, 2025 at 9:00 a.m. Eastern Time and adjourned as it was deemed advisable to do so in order to provide shareholders of record with additional time to consider the proposals being voted on at the Extraordinary General Meeting as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2025..The Extraordinary General Meeting has been adjourned to Friday, April 11, 2025, at 10

      4/10/25 4:00:00 PM ET
      $DECA
      Blank Checks
      Finance
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from March 11, 2025 to April 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a bu

      3/11/25 6:13:34 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from February 11, 2025 to March 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a

      2/11/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from January 11, 2025 to February 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of

      1/8/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from December 11, 2024 to January 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of

      12/11/24 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing o

      11/11/24 5:01:32 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

      As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

      11/6/24 12:24:36 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

      Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

      10/28/24 6:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

      Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

      10/16/24 4:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care